Derniers articles

Investigating the impact of open label design on patient-reported outcome results in prostate cancer randomized controlled trials

AbstractBackground: While open-label randomized controlled trials (RCT) are common in oncology, some concerns have...

Posté par :
Nom de la revue : Cancer Med

Anti-Telomerase CD4 + Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials

AbstractDocetaxel, cisplatin and 5-fluorouracil (DCF) chemotherapy regimen is highly effective in advanced anal squamous...

Posté par : , Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Int J Mol Sci

FOLFIRINOX De‐Escalation in Advanced Pancreatic Cancer: A Multicenter Real‐Life Study

AbstractBackground: Our study describes the feasibility and efficacy of a first-line FOLFIRINOX (5-fluorouracil...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Oncologist

Exposure-response analysis of Raltitrexed assessing liver toxicity

AbstractAim: Raltitrexed (RTX) is a thymidylate synthase inhibitor with large pharmacokinetics (PK) variability...

Posté par : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Nom de la revue : Br J Clin Pharmacol

Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study

AbstractMismatch repair-deficient (dMMR) and/or microsatellite instability-high (MSI) colorectal cancers (CRC) represent...

Posté par : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Nom de la revue : Int J Cancer

Impact of routine assessment of health-related quality of life coupled with therapeutic information on compliance with endocrine therapy in patients with non-metastatic breast cancer: protocol for a randomized controlled trial

Background: Despite its proven efficacy in reducing recurrence and improving survival, adherence to endocrine...

Posté par : Dr. Sophie PAGET-BAILLY
Nom de la revue : Trials

Surgical Management and Outcomes of Rectal Cancer with Synchronous Prostate Cancer: A Multicenter Experience from the GRECCAR Group

AbstractBackground: Synchronous prostate cancer (PC) and rectal cancer (RC) is a rare clinical situation. While...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Ann Surg Oncol

Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including platinum in patients with locally advanced or metastatic squamous cell penile carcinoma: PULSE

AbstractBackground Metastatic Squamous cell Penile Carcinoma (mSCPC) is an orphan disease with a virally induced...

Posté par : , Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Bull Cancer

NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial)

AbstractBackground: Preoperative radiochemotherapy (RCT) is recommended in France prior to total mesorectal...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : BMC Cancer

26 Mai, 2020

Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: A systemic review

AbstractBackground: Patients with severe renal impairment or undergoing hemodialysis are usually excluded from...

Posté par :
Nom de la revue : Semin Oncol

Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR)

AbstractPatients and methods: A post hoc analysis of all pathologic reports from patients with stage III CC...

Posté par : Mme. Julie HENRIQUES, Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : J Clin Oncol

Efficacy of anti-EGFR in MSI metastatic colorectal cancer depending on sporadic or familial origin

AbstractAnti-EGFR efficacy in patients with microsatellite instability (MSI) metastatic colorectal cancer (mCRC)...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : J Natl Cancer Inst

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

AbstractBackground: Modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) regimen has become a new standard for the...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : BMC Cancer

High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancer

AbstractPurpose: The aim of this study was to investigate the association between expression of insulin-like growth...

Posté par : Mme. Julie HENRIQUES
Nom de la revue : Cell Oncol (Dordr)

FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study

AbstractBackground: FOLFIRINOX regimen is the first-line reference chemotherapy (L1) in advanced pancreatic ductal...

Posté par : , Dr. Dewi VERNEREY
Nom de la revue : World J Gastrointest Oncol

Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative

AbstractBackground: The variability of definitions for time-to-event (TTE) end-points impacts the conclusions of...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE, Mme. Julie HENRIQUES
Nom de la revue : Eur J Cancer

01 Mars, 2020

Fong's Score in the Era of Modern Perioperative Chemotherapy for Metastatic Colorectal Cancer: A Post Hoc Analysis of the GERCOR-MIROX Phase III Trial

AbstractBackground: Despite improvement in colorectal liver metastasis (CLM) treatment, survival after liver...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Ann Surg Oncol

Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study

AbstractBackground: Although no data have been reported beyond second-line therapy, aflibercept is approved in this...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Clin Colorectal Cancer

[Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment]

AbstractIntroduction: Perioperative chemotherapy is the standard strategy for localized gastric cancers....

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Bull Cancer

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group

AbstractBackground: The bevacizumab-Avastin® adjuVANT (AVANT) study did not meet its primary end point of...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Ann Oncol .